EyePoint Q4 net loss $67.6M; DURAVYU wet AMD Phase 3 topline due mid-2026

EyePoint, Inc.

Net loss Q4 $67.6M ($0.81/sh) vs $41.4M ($0.64); FY net loss $232M ($3.17) vs $130.9M ($2.32).
Total net revenue Q4 $0.6M vs $11.6M, mainly from YUTIQ deferred revenue recognition.
Cash, cash equivalents & investments $306M as of Dec 31, 2025; provides runway into Q4 2027.
Both Phase 3 wet AMD trials (LUGANO, LUCIA) on track; topline data expected mid-2026. DME trials dosed.
Appointed Michael Campbell as Chief Commercial Officer for DURAVYU launch readiness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.